UPC_CoA_906/2025
Methods of Using Sustained Release Aminopyridine Compositions
Claimants
- Merz Pharmaceuticals LLC
- Merz Therapeutics GmbH
- Merz Pharma France
Respondents
- Viatris Santé
- Rian Kalden
- Patricia Rombach
- Ingeborg Simonsson
- EP2377536
Sector: Pharmaceutical & Medical
The Court of Appeal disposed of Viatris's procedural appeal (UPC_CoA_906/2025) under R.220.2 RoP as devoid of purpose under R.360 RoP. The procedural appeal concerned the Paris Local Division's panel review order confirming disregard of certain Viatris exhibits as late-filed. The Court found the appeal had no purpose because, after Viatris had filed this procedural appeal, the Paris Local Division issued its final order of 21 November 2025 rejecting Merz's application for provisional measures in Viatris's favour. Viatris could instead raise the issue of the excluded exhibits in the separate merits appeal (UPC_CoA_917/2025) brought by Merz against that final order.
Open on UPC Registry